These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 3488406)

  • 1. Characterization of the neurotoxic potential of m-methoxy-MPTP and the use of its N-ethyl analogue as a means of avoiding exposure to a possible Parkinsonism-causing agent.
    Zimmerman DM; Cantrell BE; Reel JK; Hemrick-Luecke SK; Fuller RW
    J Med Chem; 1986 Aug; 29(8):1517-20. PubMed ID: 3488406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and toxicity toward nigrostriatal dopamine neurons of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) analogues.
    Fries DS; de Vries J; Hazelhoff B; Horn AS
    J Med Chem; 1986 Mar; 29(3):424-7. PubMed ID: 3485197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistent depletion of striatal dopamine and its metabolites in mice by TMMP, an analogue of MPTP.
    Fuller RW; Hemrick-Luecke SK
    J Pharm Pharmacol; 1987 Aug; 39(8):667-9. PubMed ID: 2888865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the biological activity of several analogs of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Youngster SK; Sonsalla PK; Heikkila RE
    J Neurochem; 1987 Mar; 48(3):929-34. PubMed ID: 3492590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistent depletion of striatal dopamine in mice by m-hydroxy-MPTP.
    Fuller RW; Hemrick-Luecke SK
    Res Commun Chem Pathol Pharmacol; 1986 Aug; 53(2):167-72. PubMed ID: 3764080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistent depletion of striatal dopamine in mice by 1-methyl-4-(2-thienyl)-1,2,3,6-tetrahydropyridine (MTTP).
    Fuller RW; Robertson DW; Hemrick-Luecke SK
    Biochem Pharmacol; 1986 Jan; 35(2):143-4. PubMed ID: 3484628
    [No Abstract]   [Full Text] [Related]  

  • 7. Suppression of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity in mouse brain by piroheptine and trihexyphenidyl.
    Saitoh T
    J Neurol Sci; 1988 Feb; 83(2-3):161-6. PubMed ID: 3258627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration to C57-black mice leads to parallel decrements in neostriatal dopamine content and tyrosine hydroxylase activity.
    Mayer RA; Walters AS; Heikkila RE
    Eur J Pharmacol; 1986 Jan; 120(3):375-7. PubMed ID: 2868908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of hepatic microsomal metabolism as an in vivo detoxication pathway of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.
    Chiba K; Kubota E; Miyakawa T; Kato Y; Ishizaki T
    J Pharmacol Exp Ther; 1988 Sep; 246(3):1108-15. PubMed ID: 3262153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A high dose of MPTP overcomes the protective effect of selegiline against dopaminergic neurotoxicity.
    Fuller RW; Hemrick-Luecke SK
    J Pharm Pharmacol; 1989 Jul; 41(7):492-3. PubMed ID: 2570859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in Swiss-Webster mice from different sources.
    Heikkila RE
    Eur J Pharmacol; 1985 Oct; 117(1):131-3. PubMed ID: 3878793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repeated administration of N-methyl-4-phenyl 1,2,5,6-tetrahydropyridine to rats is not toxic to striatal dopamine neurones.
    Boyce S; Kelly E; Reavill C; Jenner P; Marsden CD
    Biochem Pharmacol; 1984 Jun; 33(11):1747-52. PubMed ID: 6610420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the effects of two 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs, 1-methyl-4-(2-thienyl)-1,2,3,6-tetrahydropyridine and 1-methyl-4-(3-thienyl)-1,2,3,6-tetrahydropyridine, on monoamine oxidase in vitro and on dopamine in mouse brain.
    Fuller RW; Robertson DW; Hemrick-Luecke SK
    J Pharmacol Exp Ther; 1987 Feb; 240(2):415-20. PubMed ID: 3100775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on levels of glutathione in the extrapyramidal system of the mouse.
    Ferraro TN; Golden GT; DeMattei M; Hare TA; Fariello RG
    Neuropharmacology; 1986 Sep; 25(9):1071-4. PubMed ID: 2430229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of selective, reversible inhibitors of monoamine oxidase on the prolonged depletion of striatal dopamine by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.
    Fuller RW; Hemrick-Luecke SK
    Life Sci; 1985 Sep; 37(12):1089-96. PubMed ID: 3875779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
    Burns RS; LeWitt PA; Ebert MH; Pakkenberg H; Kopin IJ
    N Engl J Med; 1985 May; 312(22):1418-21. PubMed ID: 2581135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent neurotoxic fluorinated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs as potential probes in models of Parkinson disease.
    Riachi NJ; Arora PK; Sayre LM; Harik SI
    J Neurochem; 1988 Apr; 50(4):1319-21. PubMed ID: 3258018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The development of amine substituted analogues of MPTP as unique tools for the study of MPTP toxicity and Parkinson's disease.
    Johannessen JN; Savitt JM; Markey CJ; Bacon JP; Weisz A; Hanselman DS; Markey SP
    Life Sci; 1987 Feb; 40(8):697-704. PubMed ID: 2433563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) does not destroy nigrostriatal neurons in the scorbutic guinea pig.
    Perry TL; Yong VW; Ito M; Jones K; Wall RA; Foulks JG; Wright JM; Kish SJ
    Life Sci; 1985 Apr; 36(13):1233-8. PubMed ID: 2858797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endogenous analogs of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: indoleamine derived tetrahydro-beta-carbolines as potential causative factors in Parkinson's disease.
    Collins MA; Neafsey EJ; Cheng BY; Hurley-Gius K; Ung-Chhun NA; Pronger DA; Christensen MA; Hurley-Gius D
    Adv Neurol; 1987; 45():179-82. PubMed ID: 3493625
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.